瀰漫大B細胞淋巴瘤
| 瀰漫大B細胞淋巴瘤 | |
|---|---|
| 類型 | B細胞淋巴瘤、aggressive B-cell non-Hodgkin lymphoma[*] |
| 分類和外部資源 | |
| 醫學專科 | 腫瘤學 |
| ICD-11 | 2A81 |
| ICD-O | M9680/3 |
| eMedicine | 202969 |
| MeSH | D016403 |
| Orphanet | 544 |
瀰漫大B細胞淋巴瘤（Diffuse large B-cell lymphoma DLBL or DLBCL）是一種常見的惡性淋巴瘤。占成人淋巴瘤患者近40%。[1]
分型
根據其基因活性，DLBL可分為2種[2]或3種[3]主要亞型:
- 活化B細胞淋巴瘤（ABC-DLBCL）
- 生發中心B細胞淋巴瘤（GCB-DLBCL）
- 原發縱隔大B細胞淋巴瘤（PMBL）
治療
標準化療方案為CHOP方案。改良的R-CHOP方案（利妥昔單抗加環磷酰胺、長春新鹼、多柔比星和潑尼松）可以改善生存率[4]，尤其是對於老年人。[2]但許多患者通過化學免疫治療獲得持久緩解，但高達50%的患者最終患有復發或難治性（R/R）疾病[5]，進行二、三線治療。
預後
生髮中心亞型的預後最好，5年生存率達60%。[2]
參考文獻
- ^ Pathobiology of the aggressive and highly aggressive non-Hodgkin's lymphomas. [2022-06-25]. （原始內容存檔於2008-01-21）.
- ^ 2.0 2.1 2.2 Turgeon, Mary Louise. Clinical hematology: theory and procedures. Hagerstown, MD: Lippincott Williams & Wilkins. 2005: 285–286. ISBN 0-7817-5007-5.
- ^ Lenz G; Wright GW; Emre NC; et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. U.S.A. September 2008, 105 (36): 13520–5. PMID 18765795. doi:10.1073/pnas.0804295105.
- ^ Sehn LH; Berry B; Chhanabhai M; et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. March 2007, 109 (5): 1857–61. PMID 17105812. doi:10.1182/blood-2006-08-038257.[永久失效連結]
- ^ Crump, Michael; Neelapu, Sattva S.; Farooq, Umar; Van Den Neste, Eric; Kuruvilla, John; Westin, Jason; Link, Brian K.; Hay, Annette; Cerhan, James R.; Zhu, Liting; Boussetta, Sami. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017-10-19, 130 (16). ISSN 0006-4971. PMC 5649550
. PMID 28774879. doi:10.1182/blood-2017-03-769620 （英語）.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||